A clinical stage II trial of simultaneous integrated boost intensity-modulated radiationtherapy in limited stage small cell lung cancer

A clinical stage II trial of simultaneous integrated boost intensity-modulated radiationtherapy in small cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-13003385

Enrollment

Unknown

Registered

2013-07-02

Start date

2013-07-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Limited stage small cell lung cancer

Interventions

Study Group:NA

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Limited small cell lung cancer proven by histopathology; 2. General state of health: ECOG 0-1 grade, life expectancy>=6 months; 3. Aged 18-75 years, male or female; 4. Without any chemotherapy; 5. Without any radiotherapy; 6. Subjects meet the following criteria for the clinical laboratory: HG>=100g/L, WBC>=3.5*10^9/L, neutrophilic leukocyte>=1.5*10^9, PLT100*10^9/L, CR>=1.5*N, TB<=2.5*N, AST and ALT<=2.5*N, AKP<=2.5*N; 7. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Carcinoma history beside SCLC; 2. Pregnant or lactational women; 3. Potentia generandi without contraception; 4. Other serious diseases, such as myocardial infarction in 6 months; 5. Participated other clinical trials in 4 weeks or at present; 6. Other anti-cancer drugs were applying; 7. With organ transplantation history.

Design outcomes

Primary

Measure	Time frame
survival rate;	—

Countries

China

Contacts

Public ContactBaosheng Li

baoshli@yahoo.com+86 0531 67626161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026